Insufficiency of annual praziquantel treatment to control Schistosoma mansoni infections in adult women: A longitudinal cohort study in rural Tanzania

Pallavi Mishra, Soledad Colombe, Ndalloh Paul, Jane Mlingi, Inobena Tosiri, Christine Aristide, Joanna Gao, Philibert Kashangaki, Honest Nagai, Samuel E. Kalluvya, Claudia J. de Dood, Paul L. Corstjens, Julius Mngara, Govert J. van Dam, Jennifer A. Downs

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Current World Health Organization (WHO) guidelines recommend annual mass drug administration using praziquantel in areas with high schistosome endemicity. Yet little is known about incidence and reinfection rates after treatment in women with frequent exposure to schistosomes. We sought to quantify response to anti-schistosome treatment and incident S. mansoni infections in a cohort of rural women living in a schistosome-endemic area of northwest Tanzania. METHODS AND PRINCIPAL FINDINGS: We enrolled women with and without S. mansoni infection into a 12-month longitudinal cohort. Every 3 months, women were tested for schistosome infection using microscopic examinations for ova on filtered urine, Kato Katz slides, and serum Circulating Anodic Antigen (CAA). Those with schistosome infection received treatment with praziquantel 40 mg/kg according to the standard of care. We studied 35 women who were S. mansoni positive by stool microscopy and 46 women without schistosome infection who returned for at least one follow-up. Of the women who were initially infected, 14 (40 were schistosome-positive at a follow-up visit. Four women developed incident infections, for a cumulative incidence of 8.7.99 per 100 person-months throughout the year among initially uninfected women. Only 3 women were egg-positive at any follow-up. Women with persistent, recurrent, or incident infection during the study period were significantly younger (p = 0.032) and had fewer children than women who remained uninfected or those who cleared the infection and did not experience recurrence (p = 0.003). Having fewer children remained significant after controlling for age (p = 0.023). There was no difference in initial intensity of infection by CAA or stool egg count, HIV status, or socioeconomic status. Although most water contact behaviors were comparable between the two groups, women with recurrent or incident schistosome infections were significantly more likely to have recently swum in the lake (p = 0.023). CONCLUSIONS: Our data suggests that annual praziquantel treatment reduces intensity of schistosome infections but is insufficient in providing stable parasite eradication in over a third of women in endemic communities. Furthermore, microscopy lacks adequate sensitivity to evaluate efficacy of treatment in this population. Our work demonstrates that further investigation into treatment efficacy and reinfection rates is warranted and suggests that increased frequency of praziquantel treatment is needed to improve cure rates in high-risk populations.
Original languageEnglish
JournalPLoS Neglected Tropical Diseases
Volume13
Issue number11
Pages (from-to)e0007844
ISSN1935-2727
DOIs
Publication statusPublished - 1-Nov-2019

Keywords

  • Adult
  • Animals
  • Anthelmintics
  • Female
  • Humans
  • Incidence
  • Longitudinal Studies
  • Mass Drug Administration
  • Praziquantel
  • Rural Population
  • Schistosoma mansoni
  • Schistosomiasis mansoni
  • Tanzania
  • Treatment Outcome
  • Young Adult

Fingerprint

Dive into the research topics of 'Insufficiency of annual praziquantel treatment to control Schistosoma mansoni infections in adult women: A longitudinal cohort study in rural Tanzania'. Together they form a unique fingerprint.

Cite this